FDA Issues Draft Guidance on Patient Counseling Info for Labeling
FDA Issues Draft Guidance on Patient Counseling Info for Labeling
FDA has released its draft guidance, Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products—Content and Format. The document gives guidance on the development of patient counseling information on labels has required under § 201.57(c)(18) (21 CFR 201.57(c)(18)). The guidance is intended to assist applicants with deciding what topics to include in a label’s patient counseling information section as well as the presentation and organization of those topics.
A final rule amending requirements for the content and formatting of labeling, published on Jan. 24, 2006, created the new required section, Patient Counseling Information (§ 201.57(c)(18)). The section summarizes the information that a healthcare provider should convey to a patient. According to the draft guidance, patient-counseling information must contain information necessary for patients to use the drug safely and effectively and, if applicable, reference to FDA-approved patient labeling.
Source: FDA.gov
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
